| Code | CSB-RA011649MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Imneskibart, targeting IL2RA (interleukin-2 receptor alpha chain, CD25). IL2RA is the alpha subunit of the high-affinity IL-2 receptor complex, playing a critical role in T cell activation, proliferation, and immune response regulation. This receptor is constitutively expressed on regulatory T cells and upregulated on activated T cells and B cells. Aberrant IL2RA expression is associated with various autoimmune diseases, transplant rejection, and hematologic malignancies, particularly adult T-cell leukemia/lymphoma and certain subtypes of acute lymphoblastic leukemia.
Imneskibart is a therapeutic antibody developed for the treatment of immune-mediated conditions through selective modulation of IL-2 signaling pathways. This biosimilar provides researchers with a valuable tool for investigating IL2RA-mediated immune mechanisms, studying T cell biology, exploring autoimmune disease pathogenesis, and evaluating potential therapeutic interventions. The antibody enables detailed examination of IL-2 receptor dynamics and their role in immune homeostasis and dysregulation.
There are currently no reviews for this product.